The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked CRA to evaluate the policies that host governments of middle-income countries use to encourage investment in innovative activities and the implications for future innovation. CRA consultants looked at eight countries and concluded that there are six key lessons that appear to be critical for success. Read more in the article here:
An analysis of the effect of drug pricing provisions in the Build Back Better Act on pharmaceutical innovation
Charles River Associates has previously assessed the implications of proposals to implement international reference pricing in the US and found they would...